Status
Conditions
Treatments
About
The goal of this clinical trial is to learn about the safety and tolerability of transcranial direct current stimulation (tDCS) combined with cognitive training in adults with Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD).
The main question it aims to answer is:
Is tDCS safe and well-tolerated in adults with ASD and/or ADHD?
Researchers will compare active tDCS to a sham (placebo-like) stimulation to evaluate safety and tolerability.
Participants will:
Receive either active or sham tDCS for 20 minutes daily over 10 consecutive workdays
Undergo stimulation with the anode placed at F3 and the cathode at Fp2
Complete daily cognitive training exercises using the NeuronUP platform during stimulation
Attend baseline and follow-up assessments to monitor for any side effects or discomfort related to the intervention
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adults aged 18 to 55 years
Clinical diagnosis of Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed via medical records or structured clinical interview
Able to provide informed consent
Fluent in the language used for assessments and cognitive training tasks
Stable medication regimen (if applicable) for at least 4 weeks prior to enrollment
Willing and able to attend 10 consecutive weekday sessions and follow-up assessment
Exclusion criteria
History of epilepsy, seizures, or significant neurological disorder (e.g., traumatic brain injury, stroke)
Current diagnosis of psychotic disorder or bipolar disorder
Presence of metal implants in the head (excluding dental work), pacemaker, or other contraindications to tDCS
Current substance use disorder (within past 6 months)
Pregnant or planning to become pregnant during the study period
Participation in another intervention study within the last 30 days
Any condition that, in the opinion of the investigators, may make participation unsafe or interfere with study procedures
Primary purpose
Allocation
Interventional model
Masking
25 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal